Literature DB >> 1380976

The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.

F J Dumont1, M J Staruch, S L Koprak, J J Siekierka, C S Lin, R Harrison, T Sewell, V M Kindt, T R Beattie, M Wyvratt.   

Abstract

FK-506 inhibits Ca(2+)-dependent transcription of lymphokine genes in T cells, and thereby acts as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear whether these immunosuppressive and toxic effects result from interference with related biochemical processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant cytosolic protein with cis-trans peptidyl-prolyl isomerase activity (PPIase) activity. Because rapamycin (RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting T cell responses to lymphokines, such an interaction with FKBP-12 is not sufficient to mediate immunosuppression. Recently, it was found that the complex of FKBP-12 with FK-506, but not with RAP, inhibits the phosphatase activity of calcineurin. Here, we used L-685,818, the C18-hydroxy, C21-ethyl derivative of FK-506, to explore further the role of FKBP-12 in the immunosuppressive and toxic actions of FK-506. Although L-685,818 bound with high affinity to FKBP-12 and inhibited its PPIase activity, it did not suppress T cell activation, and, when complexed with FKBP-12, did not affect calcineurin phosphatase activity. However, L-685,818 was a potent antagonist of the immunosuppressive activity of both FK-506 and RAP. Moreover, L-685,818 did not induce any toxicity in dogs and rats or in a mouse model of acute FK-506 nephrotoxicity, but it blocked the effect of FK-506 in this model. Therefore, FK-506 toxicity involves the disruption of biochemical mechanisms related to those implicated in T cell activation. Like immunosuppression, this toxicity is not due to the inhibition of the PPIase activity of FKBP-12, but may be linked to the inhibition of the phosphatase activity of calcineurin by the drug FKBP-12 complex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380976      PMCID: PMC2119351          DOI: 10.1084/jem.176.3.751

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  The Hsp56 component of steroid receptor complexes binds to immobilized FK506 and shows homology to FKBP-12 and FKBP-13.

Authors:  A W Yem; A G Tomasselli; R L Heinrikson; H Zurcher-Neely; V A Ruff; R A Johnson; M R Deibel
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

2.  The regulation of glycogen metabolism. Purification and characterisation of protein phosphatase inhibitor-1 from rabbit skeletal muscle.

Authors:  G A Nimmo; P Cohen
Journal:  Eur J Biochem       Date:  1978-06-15

3.  The metabolism of drugs in isolated rat hepatocytes. A comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions.

Authors:  R E Billings; R E McMahon; J Ashmore; S R Wagle
Journal:  Drug Metab Dispos       Date:  1977 Nov-Dec       Impact factor: 3.922

4.  FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics.

Authors:  H Hatanaka; T Kino; S Miyata; N Inamura; A Kuroda; T Goto; H Tanaka; M Okuhara
Journal:  J Antibiot (Tokyo)       Date:  1988-11       Impact factor: 2.649

Review 5.  Antigen-specific, major histocompatibility complex-restricted T cell receptors.

Authors:  P Marrack; C Hannum; M Harris; K Haskins; R Kubo; M Pigeon; R Shimonkevitz; J White; J Kappler
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

6.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

7.  Activation of calcineurin by limited proteolysis.

Authors:  A S Manalan; C B Klee
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

8.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

9.  Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat.

Authors:  P H Whiting; J Woo; B J Adam; N U Hasan; R J Davidson; A W Thomson
Journal:  Transplantation       Date:  1991-08       Impact factor: 4.939

10.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins.

Authors:  G Fischer; B Wittmann-Liebold; K Lang; T Kiefhaber; F X Schmid
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

View more
  39 in total

1.  Curcumin suppresses T cell activation by blocking Ca2+ mobilization and nuclear factor of activated T cells (NFAT) activation.

Authors:  Christian Kliem; Anette Merling; Marco Giaisi; Rebecca Köhler; Peter H Krammer; Min Li-Weber
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

2.  Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo.

Authors:  Betty Chan; Garrett Greenan; Frank McKeon; Tom Ellenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

3.  FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition.

Authors:  G Baughman; G J Wiederrecht; N F Campbell; M M Martin; S Bourgeois
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

4.  Ca2+/calcineurin-inhibited adenylyl cyclase, highly abundant in forebrain regions, is important for learning and memory.

Authors:  F A Antoni; M Palkovits; J Simpson; S M Smith; A L Leitch; R Rosie; G Fink; J M Paterson
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

5.  Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient?

Authors:  Aileen J Anderson; Daniel L Haus; Mitra J Hooshmand; Harvey Perez; Christopher J Sontag; Brian J Cummings
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

6.  Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole.

Authors:  James Simpson; Adrienn Pálvölgyi; Ferenc A Antoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-03       Impact factor: 3.000

7.  Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats.

Authors:  Gwenn E McLaughlin; Michelle Schober; Maria Perez; Phillip Ruiz; Bernard W Steele; Carolyn Abitbol
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

8.  Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin.

Authors:  S Halpain; A Hipolito; L Saffer
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

9.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Authors:  William J Steinbach; Wiley A Schell; Jill R Blankenship; Chiatogu Onyewu; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.